Related references
Note: Only part of the references are listed.Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study
RP Whitehead et al.
INVESTIGATIONAL NEW DRUGS (2006)
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
CA Townsley et al.
BRITISH JOURNAL OF CANCER (2006)
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers
RL Coleman et al.
GYNECOLOGIC ONCOLOGY (2006)
Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study
E Winquist et al.
INVESTIGATIONAL NEW DRUGS (2006)
Estimating the cost of new drug development: Is it really $802 million?
CP Adams et al.
HEALTH AFFAIRS (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: A phase II study
S Niho et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II trial of imatinib (Gleevec (R)) in patients with metastatic renal cell carcinoma
J Vuky et al.
INVESTIGATIONAL NEW DRUGS (2006)
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma
ML Rothenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: A prospective phase II study
YM Chen et al.
JOURNAL OF CHEMOTHERAPY (2005)
A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study
GK Dy et al.
ANNALS OF ONCOLOGY (2005)
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study
AN Gordon et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: A Minnie Pearl Cancer Research Network phase II trial
David R. Spigel et al.
CLINICAL LUNG CANCER (2005)
Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval
J Goffin et al.
CLINICAL CANCER RESEARCH (2005)
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
S Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic oncology group study
RJ Schilder et al.
CLINICAL CANCER RESEARCH (2005)
Marimastat in the treatment of patients with biochemically relapsed prostate cancer: A prospective randomized, double-blind, phase I/II trial
E Rosenbaum et al.
CLINICAL CANCER RESEARCH (2005)
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein - A phase II clinical trial
LM Krug et al.
CANCER (2005)
A Multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer
KD Miller et al.
CLINICAL CANCER RESEARCH (2005)
Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2 -: 39810:: A Phase II trial of cancer and leukemia group B
G Clamon et al.
CANCER (2005)
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer
S Modi et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer
K Rao et al.
PROSTATE (2005)
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group
CM Canil et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase II trial of ZD1839 (Iressa (TM)) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer
MJ MacKenzie et al.
INVESTIGATIONAL NEW DRUGS (2005)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
MB Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21-day infusion to patients with advanced ovarian carcinoma
R Advani et al.
CANCER (2004)
The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
A Ziada et al.
PROSTATE (2004)
Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
R Pérez-Soler et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer
JV Heymach et al.
ANNALS OF ONCOLOGY (2004)
Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice
WR Parulekar et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma
NA Dawson et al.
CLINICAL CANCER RESEARCH (2004)
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
J Rinehart et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Adjuvant interferon therapy for melanoma: High-dose, low-dose, no dose, which dose?
LM Schuchter
JOURNAL OF CLINICAL ONCOLOGY (2004)
A randomized phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer
WM Stadler et al.
CLINICAL CANCER RESEARCH (2004)
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
MA Cobleigh et al.
SEMINARS IN ONCOLOGY (2003)
Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma
B Drucker et al.
INVESTIGATIONAL NEW DRUGS (2003)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer
SRD Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
M Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase II study of the farnesyl transferase inhibitor r115777 in patients with advanced non-small-cell lung cancer
AA Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)
AM Oza et al.
GYNECOLOGIC ONCOLOGY (2003)
The price of innovation: new estimates of drug development costs
JA DiMasi et al.
JOURNAL OF HEALTH ECONOMICS (2003)
Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma
RJ Motzer et al.
INVESTIGATIONAL NEW DRUGS (2003)
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
MA Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Randomized discontinuation design: Application to cytostatic antineoplastic agents
GL Rosner et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan
S Sharma et al.
ANNALS OF ONCOLOGY (2002)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group Report
B Coudert et al.
EUROPEAN JOURNAL OF CANCER (2001)
Application of a new multinomial phase II stopping rule using response and early progression
S Dent et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Clinical trial designs for cytostatic agents: Are new approaches needed?
EL Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
M Buyse et al.
LANCET (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
